eccogene glp-1 Enters Exclusive License Agreement With AstraZeneca to Develop and Commercialize Small Molecule Receptor Agonist ECC5004 for Cardiometabolic Diseases AstraZeneca Presents Elecoglipron Data at

Depression: A meta-analysis of 5 RCTs (n=574) found that NAC significantly improved depressive symptoms, particularly in individuals with high baseline symptom severity (Fernandes et al., J Clin Psychiatry, 2016) [73]

Abstract: We demonstrated for the first time that a marine-derived antimicrobial peptide (AMP), Sph_12-38, exhibit high antimicrobial activity against P

23

Blood testing also cannot prove whether a medication caused a change in mood or motivation

The emerging gut-ovary-brain axis framework that ovarian dysfunction in PCOS is partly mediated by gut microbiome imbalance and altered neuroendocrine signaling is generating serious research attention

This pronounced gradient renders GSH an effective and sensitive trigger for redox-responsive drug delivery systems